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Background
FMF is a systemic auto-inflammatory disorder, character-
ized by recurrent episodes of fever and serosal inflamma-
tion. The MEF gene, which is associated with FMF,
encodes for the protein pyrin. FMF associated mutations,
interrupt with pyrin normal function, leading to activation
of the innate immune system and overexpression of IL-1b,
and consequently to a systemic inflammatory response.
Toll-like receptors (TLRs) play an essential role in the
innate immune responses, by recognition of pathogen-
associated molecular patterns and endogenous peptides.
TLRs trigger a cascade of signaling events, leading to cyto-
kine production. TLR2 is implicated in several inflamma-
tory conditions, but its role in the pathogenesis of FMF is
not completely clear.
Objectives
To study the role of TLR2 in the inflammatory process of
FMF.
Materials and methods
We tested TLR2 naïve expression on monocytes of FMF
attack-free patients (n=20) by FACS. We further tested
the effect of sera from FMF patients in acute attack (n=6)
on TLR2 expression by monocytes of healthy controls.
The role of TLR2 was studied in respect to MEFV muta-
tion, performed in THP-1 cells. TLR2 downstream sig-
naling was studied by ELISA to measure IL-1b secretion,
or by Western-blot to measure NF-B.
Results
FMF attack-free patients have increased CD14+TLR2+
cell-count, as compared to healthy donors. High dose of
colchicine treatment (≥2mg/d) inhibited this increased
expression of TLR2 in FMF patients. Colchicine in vitro
also inhibited the levels of TLR2 expression on THP-1
cells. Sera from FMF patients in acute attack induced
TLR2 expression by both monocytes of healthy donors
and THP-1 cells, and IL-1b secretion in healthy mono-
cytes, and colchicine inhibited this induction. Further-
more, TLR2 agonist (Pam2CSK4) increased the secretion
of IL-1b by PBMCs of healthy donors, and this activation
was inhibited by colchicine. In MEFV -mutated THP-1
cells, TLR2 expression was spontaneously up-regulated by
3.8 folds, while TLR4 expression was elevated by 2 folds as
compared to wild-type. Wild-type THP-1 cells presented
elevated NF-B expression when cultured with
Pam2CSK4, whereas colchicine treatment abolished this
expression. MEFV-mutated THP-1 cells expressed
elevated levels of NF-B, as compared to their wild-type
counterparts.
Conclusion
TLR2 activation is up-regulated in monocytes of FMF
patients, and colchicine inhibits this up-regulation in-vitro
and in-vivo. Elevated expression of TLR2 promotes IL-1b
production, and thus contribute to the uncontrolled
inflammation manifested in FMF.
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